Cogent Biosciences, Inc.
COGT
NASDAQ·Healthcare·Biotechnology·Mkt cap $6.0B
$34.68
▼ -0.91%
P/E
-13.76
Mkt Cap
$6.0B
52-Wk Range
$11.60–$43.73
52-Week Range
$11.60 - $43.73
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 191.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Selective KIT D816V inhibitor with differentiated mechanism of action
- Focus on genetically defined diseases with clear patient populations
- Strategic partnerships with established biotech firms for development and commercialization
- Experienced management team in precision medicine and oncology drug development
Bear Case
1 risk
- Low volatility (beta 0.3).
Growth
Stable outlook
Clinical development progress of CGT9486 in systemic mastocytosis and GIST indications
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Stable
+0.6% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying COGT right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 6, 2026
AUG 10, 2026
Reported EPS of -$0.52 vs -$0.56 consensus (+6.3% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+6.3%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
4 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Piper Sandler · Aug 17, 2026
vs Industry
How COGT stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related